News
CHMP recommends Nucala for three new indications
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended approval for GlaxoSmithKline’s Nucala (mepolizumab) in three additional eosinophil-driven diseases.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended approval for GlaxoSmithKline’s Nucala (mepolizumab) in three additional eosinophil-driven diseases.